Madrigal: Rezdiffra efficacy consistent across MASH genetic risk variants
New Journal of Hepatology data from a secondary analysis of Madrigal's Phase 3 MAESTRO-NASH trial showed Rezdiffra had broadly consistent benefits on liver disease measures across common genetic risk variants tied to MASH progression. Findings support use across genetically diverse patients, reducing the need to segmen